Cystic Fibrosis is a rare inherited disorder that causes loss of lung function and damages the digestive system. It is found that the Caucasian population has a higher prevalence of Cystic Fibrosis. For years there was no treatment available targeting the underlying cause, however, this changed in 2012 with the launch of Vertex Pharma’s Kalydeco.
Early screening and newly available therapies undoubtedly have led to an increase in the survival of patients and improved the pace of the market size growth. As per Delveinsight, the total Cystic Fibrosis cases in the six major markets (i.e. the United States, and EU5 (the United Kingdom, Germany, France, Italy, and Spain)) are projected to increase from 69,400 cases in 2020 with a CAGR of 3.5%. Similarly, among the 6MM, the United States accounted for the highest market size, with 80.9% of the market share of Cystic Fibrosis as compared to EU5 (19.1%). The total market size of Cystic Fibrosis in 6MM was USD 5,141 Million in 2020.
Along with the increasing prevalence, the development of new therapies by key players including Arrowhead Pharmaceuticals, Eloxx Pharmaceuticals, Ionis Pharmaceuticals, Verona Pharma, Proteostasis Therapeutics (PTI), Vertex Pharmaceuticals, Translate Bio, ProQR Therapeutics will further drive the increase in the Cystic Fibrosis market in the coming years.
For more details, visit: Cystic Fibrosis Treatment Options